Occurrence, course and risk factors of depression during antiviral treatment for chronic hepatitis C in patients with inherited bleeding disorders: A prospective study

Haemophilia

Volumn 15, Issue 2, 2009, Pages 544-551

  Fransen van de Putte, D E ^a   Fischer, K ^a,b   Posthouwer, D ^a   Van Erpecum, K ^b   Mauser Bunschoten, E P ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Depression; Haemophilia; Hepatitis C; Interferon; Prediction

Indexed keywords

ANTIDEPRESSANT AGENT; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; HEMOPHILIA A; HEMOPHILIA B; HEPATITIS C; HUMAN; MALE; MENTAL DISEASE; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RELAPSE; RISK FACTOR; TREATMENT DURATION; TREATMENT RESPONSE; VON WILLEBRAND DISEASE;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; BLOOD COAGULATION DISORDERS, INHERITED; DEPRESSIVE DISORDER; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON TYPE I, RECOMBINANT; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK FACTORS; YOUNG ADULT;

EID: 63349108745     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01940.x     Document Type: Article

References (36)

1. Posthouwer D, Plug I, van der Bom JG, Fischer K, Rosendaal FR, Mauser-Bunschoten EP. Hepatitis C infection among Dutch haemophilia patients: A nationwide cross-sectional study of prevalence and antiviral treatment. Haemophilia 2005; 11: 270-5.
2. Franchini M, Rossetti G, Tagliaferri A et al. The natural history of chronic hepatitis C in a cohort of HIV-negative Italian patients with hereditary bleeding disorders. Blood 2001; 98: 1836-41.
3. Posthouwer D, Makris M, Yee TT et al. Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study. Blood 2007; 109: 3667-71.
4. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
5. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958-65.
6. Posthouwer D, Mauser-Bunschoten EP, Fischer K, Makris M. Treatment of chronic hepatitis C in patients with haemophilia: A review of the literature. Haemophilia 2006; 12: 473-8.
7. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36: S237-44.
8. Cai W, Khaoustov VI, Xie Q, Pan T, Le W, Yoffe B. Interferon-alpha-induced modulation of glucocorticoid and serotonin receptors as a mechanism of depression. J Hepatol 2005; 42: 880-7.
9. Bonaccorso S, Marino V, Puzella A et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002; 22: 86-90.
10. Bonaccorso S, Puzella A, Marino V et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res 2001; 105: 45-55.
11. Loftis JM, Hauser P. The phenomenology and treatment of interferon-induced depression. J Affect Disord 2004; 82: 175-90.
12. Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 2003; 64: 708-14.
13. Raison CL, Borisov AS, Broadwell SD et al. Depression during pegylated interferon-alpha plus ribavirin therapy: Prevalence and prediction. J Clin Psychiatry 2005; 66: 41-8.
14. Bonaccorso S, Marino V, Biondi M, Grimaldi F, Ippoliti F, Maes M. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord 2002; 72: 237-41.
15. Castera L, Constant A, Henry C et al. Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C. Aliment Pharmacol Ther 2006; 24: 1223-30.
16. Hunt CM, Dominitz JA, Bute BP, Waters B, Blasi U, Williams DM. Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci 1997; 42: 2482-6.
17. Beck AT, Steer RA. Manual for the Beck Depression Inventory I-A. San Antonio, TX: Psychological Corporation, 1993.
18. Posthouwer D, Fischer K, De Heusden N, Mauser-Bunschoten EP. Pegylated interferon and ribavirin combination therapy for chronic hepatitis C in patients with congenital bleeding disorders: A single-centre experience. Haemophilia 2007; 13: 98-103.
19. Beck AT, Steer RA, Garbin GM. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clin Psychol Rev 1988; 8: 77-100.
20. Dieperink E, Ho SB, Thuras P, Willenbring ML. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003; 44: 104-12.
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV, 4th edn. Washington, DC: American Psychiatric Association, 1994.
22. Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation, 1996.
23. Moore MJ, Moore PB, Shaw PJ. Mood disturbances in motor neurone disease. J Neurol Sci 1998; 160(Suppl. 1): S53-6.
24. Golden J, O'Dwyer AM, Conroy RM. Depression and anxiety in patients with hepatitis C: Prevalence, detection rates and risk factors. Gen Hosp Psychiatry 2005; 27: 431-8.
25. Posthouwer D, Plug I, van der Bom JG, Fischer K, Rosendaal FR, Mauser-Bunschoten EP. Hepatitis C and health-related quality of life among patients with hemophilia. Haematologica 2005; 90: 846-50.
26. Raison CL, Broadwell SD, Borisov AS et al. Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun 2005; 19: 23-7.
27. Loftis JM, Socherman RE, Howell CD et al. Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C. Neurosci Lett 2004; 365: 87-91.
28. Schafer A, Scheurlen M, Weissbrich B, Schottker K, Kraus MR. Sustained virological response in the antiviral therapy of chronic hepatitis C: Is there a predictive value of interferon-induced depression? Chemotherapy 2007; 53: 292-9.
29. Asnis GM, De La Garza R. Interferon-induced depression in chronic hepatitis C: A review of its prevalence, risk factors, biology, and treatment approaches. J Clin Gastroenterol 2006; 40: 322-35.
30. Horikawa N, Yamazaki T, Izumi N, Uchihara M. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: A prospective study. Gen Hosp Psychiatry 2003; 25: 34-8.
31. Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM. Hepatitis C, interferon alfa, and depression. Hepatology 2000; 31: 1207-11.
32. Barbui C, Furukawa TA, Cipriani A. Effectiveness of paroxetine in the treatment of acute major depression in adults: A systematic re-examination of published and unpublished data from randomized trials. CMAJ 2008; 178: 296-305.
33. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: A meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008; 5: E45.
34. Turner MS, May DB, Arthur RR, Xiong GL. Clinical impact of selective serotonin reuptake inhibitors therapy with bleeding risks. J Intern Med 2007; 261: 205-13.
35. Musselman DL, Lawson DH, Gumnick JF et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 344: 961-6.
36. Raison CL, Woolwine BJ, Demetrashvili MF et al. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther 2007; 25: 1163-74.